A nanoscale drug carrier capable of crossing the blood-brain barrier. Said carrier can target brain lesions (brain tumors or other neurodegenerative diseases). The targeting drug carrier capable of crossing the blood-brain barrier comprises all-heavy-chain human ferritin or a functional fragments reconstituted structure or a mutant thereof. The manner for crossing the blood-brain barrier of the drug carrier is receptor-mediated transcytosis. The drug carrier provides an effective nanoscale drug carrier for the treatment of brain tumors or other neurodegenerative diseases.

The present invention relates to a nanoparticle or nanoformulation comprising two or more bioactive phytochemicals from turmeric. The nanoparticle or nanoformulation preferably comprises curcumin or curcuminoids and water-soluble peptides comprising turmerin. The waster-soluble peptides comprising turmerin are preferably present in a water-soluble extract of turmeric which comprises turmerin. Methods for producing the nanoparticle or nanoformulation are also disclosed.

A nano-pharmaceutical formulation, comprising zein nanoparticles, icariin (ICA) or a pharmaceutically acceptable salt thereof encapsulated within the zein nanoparticles, at least one solubilizer, wherein the at least one solubilizer comprises D-a-Tocopherol polyethylene glycol 1000 succinate (TPGS), and one or more pharmaceutical penetration enhancers is provided. Methods of enhancing libido by administering a composition as described herein is also provided.

The task of the invention is therefore making available transfer capsules that are taken up by the target cell type and permanently or transiently modify the target cell, without exerting any toxic effects on the cell during this process.

The solution according to the invention consists of the use of monodisperse cores, so as to produce polyelectrolyte nanocapsules having cell-specific sizes from them. The sizes for hematopoietic cells are in a range of 20-80 nm, preferably in a range of 40-60 nm. In this regard, the sizes of the particles must be in a very narrow range, so as to prevent toxic effects from occurring. In order to keep the toxicity of the nanocapsules low, it is furthermore important to remove the nanoparticles around which the capsules are built up (cores) before use. Methods in this regard are known from the state of the art (for example dissolution by means of EDTA).

A further task is the stabilization of the transfer capsules.

The solution according to the invention consists in the modification of the capsules, the layers and/or the cargo to be packed, by means of functional groups, which allows stabilization and thereby long-term storage at room temperature.

The third task is the targeted introduction of the transfer capsules.

The solution according to the invention is a functionalization of the layers by way of chemical modifications and/or supplementing of the layers with antibodies, proteins or peptides.

Methods and compositions for inducing long-term tolerance by hybrid nanoparticles are provided. Compositions and formulations comprising hybrid nanoparticles with inherent affinity for innate immune cells are provided.

Disclosed is a curcumin nanoparticle, including curcumin as core material and a wall material, where a weight ratio of the curcumin to the wall material is (5.5-7.5):100, and the wall material includes gum arabic and zein in a weight ratio of (1-5):5. The disclosure further provides a method of making the curcumin nanoparticle and a curcumin beverage containing the curcumin nanoparticle.

Cancer treatment methods using thermotherapy and/or enhanced immunotherapy are disclosed herein. In one embodiment, the method comprising the steps of: (i) applying controlled thermal energy at 40-43° C. for a first predetermined time period to damage and weaken tumor cells of a tumor in a patient; (ii) administering pulsed high intensity focused ultrasound (pHIFU) in a first ultrasound mode to the tumor cells in the patient so as to damage the tumor cells without increasing the thermal energy; and (iii) administering low intensity focused ultrasound (LIFU) in a second ultrasound mode to further damage the tumor cells at a temperature of 39-43° C. for a second predetermined time period while performing observation of the tumor cells by ultrasonic thermometry.

Provided are a programmed cell death protein 1 (PD-1)-decorated nanocage and use thereof. The PD-1-decorated nanocage (PdNC) of the present disclosure may block PD-1 and programmed cell death-ligand (PD-L) signaling and may induce anti-tumor immunity activation at two immune checkpoints of tumor microenvironment (TME) (effector phase) and tumor-draining lymph node (TDLN) (innate phase), thereby increasing the adaptability of PD-1 and PD-L blockade-based therapy. Accordingly, it may be applied to various kinds of cancer therapies.

The present invention is in the field of aqueous emulsions that dry into water-insoluble or water-resistant structures that are useful for active packaging, manufactured devices and components, and other applications. The aqueous emulsions of the present invention comprise biopolymers, metal in the form of a salt, nanoparticles or metal oxide nanoparticles, essential oil, and additives such as surfactants and plasticizers. When the components of the emulsion are mixed following the distinctive method of preparation, a water-soluble fluid is obtained, which, upon drying, becomes a water-insoluble or water-resistant solid exhibiting antimicrobial, antioxidative, and other useful properties including tensile strength, elasticity, transparency. The obtained fluid may be applied by spraying, pouring, injecting, 3-D printing, or otherwise formed into a solid product of any geometrical shape including film, foil, or other 3-D shape.

Protein-based nanoparticles and methods of forming such protein-based nanoparticles via electrohydrodynamic jetting methods are provided. The nanoparticle may comprise a water-soluble protein having an average molecular weight of ≥ about 8 kDa and < about 700 kDa. In certain variations, the water-soluble protein is cross-linked (e.g., with an optional crosslinking agent) and defines a mesh structure having an average linear mesh size of ≥ about 1 nm to ≤ about 4 nm. Methods of making such nanoparticles may include jetting a liquid comprising the water-soluble protein through a nozzle, followed by exposing the liquid to an electric field sufficient to solidify the liquid and form the protein-based nanoparticles described above.

C